⚠️ RESEARCH PURPOSES ONLY — This compound is not FDA authorized for human consumption. All referenced data is presented for informational and educational purposes only.
CJC-1295 / Ipamorelin 10MG
$55.00
Availability: 10 in stock
How It Works
Two complementary pituitary receptor pathways activated simultaneously for synergistic GH pulse enhancement
CJC-1295: GHRH Receptor Activation
CJC-1295 (Modified GRF 1-29) is the GHRH receptor agonist component. It binds GHRH-R on pituitary somatotrophs, stimulating cAMP production and GH synthesis. The four DPP-IV-resistant amino acid substitutions extend bioavailability to ~30 minutes, enabling a sustained window of GHRH-R activation per dose.
- GHRH-R agonism — cAMP-mediated GH synthesis
- ~30-minute half-life for time-matched dosing
- Cortisol, thyroid, prolactin unaffected
Ipamorelin: Ghrelin Receptor Activation
Ipamorelin is the GHSR-1a (ghrelin receptor) agonist component. It binds a distinct receptor population on somatotrophs via a phospholipase C / IP3 intracellular pathway — separate from the cAMP route used by GHRH. This complementary signaling allows both pathways to be active simultaneously without receptor competition.
- GHSR-1a agonism — PLC/IP3 intracellular pathway
- No cortisol, ACTH, or prolactin co-secretion
- ~2-hour half-life — pulsatile GH release
Dual-Pathway Synergistic GH Amplification
When GHRH-R and GHSR-1a are activated simultaneously, GH pulse amplitude exceeds what either compound produces alone. Preclinical data show this additive-to-synergistic interaction: each pathway potentiates the other's pituitary response, producing larger GH pulses without proportionally increasing side effects.
- Additive GH pulse amplitude vs either alone
- Somatostatin suppression potentiated by GHSR agonism
- Physiologic pulsatile pattern preserved
What Research Has Shown
Findings from component-level studies — Raun et al. 1998 (ipamorelin); Teichman et al. 2006 (CJC-1295)
Research Applications
Primary areas of investigation
Dual-Pathway GH Stimulation
Simultaneous GHRH-R and GHSR-1a activation produces additive GH pulse amplification — a model for studying maximal pituitary GH secretory capacity while maintaining physiologic pulse architecture.
Raun et al. 1998 ↗Physiologic Secretion Patterns
The short half-lives of both components (~30 min for CJC-1295; ~2 hr for ipamorelin) preserve pulsatile GH release — enabling research into GH pulse physiology without continuous baseline elevation.
Frieboes et al. 2004 ↗Selectivity vs GHRP-6 Blends
CJC-1295/Ipamorelin is studied as a high-selectivity alternative to CJC-1295/GHRP-6 combinations — preserving GH stimulation amplitude while eliminating cortisol and prolactin co-secretion associated with GHRP-6.
Raun et al. 1998 ↗Complementary Signaling Pathways
GHRH-R signals via cAMP/PKA while GHSR-1a signals via PLC/IP3 — distinct second messenger cascades that do not compete. This orthogonal mechanism makes the combination a research model for studying receptor cross-talk in neuroendocrine signaling.
Kojima & Kangawa 2001 ↗Compound Information
Technical specifications